The rates and routes of lethal systemic spread in breast cancer are poorly understood owing
to a lack of molecularly characterized patient cohorts with long-term, detailed follow-up data…

Background Metastatic breast cancer (MBC) treatment has changed substantially over time,
but we do not know whether survival post-metastasis has improved at the population level. …

Purpose We examined racial/ethnic differences in the usage and results of germ-line
multiple-gene sequencing (MGS) panels to evaluate hereditary cancer risk. Methods We collected …

In cascade testing, genetic testing for an identified familial pathogenic variant extends to
disease-free relatives to allow genetically targeted disease prevention. We evaluated the results …

Importance The effects of breast cancer incidence changes and advances in screening and
treatment on outcomes of different screening strategies are not well known. Objective To …

In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant
trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials …

The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved
pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer…

BACKGROUND The IBIS/Tyrer‐Cuzick model is used clinically to guide breast cancer
screening and prevention, but was developed primarily in non‐Hispanic White women. Little is …

Purpose The early months of the COVID-19 pandemic led to reduced cancer screenings
and delayed cancer surgeries. We used insurance claims data to understand how breast …

Genomic changes observed across treatment may result from either clonal evolution or
geographically disparate sampling of heterogeneous tumors. Here we use computational …